Entering text into the input field will update the search result below

Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2020 Results - Earnings Call Transcript

Apr. 06, 2021 11:46 AM ETStealth BioTherapeutics Corp (MITO)
SA Transcripts profile picture
SA Transcripts

Stealth BioTherapeutics Corp (NASDAQ:MITO) Q4 2020 Results Earnings Conference Call April 6, 2021 8:30 AM ET

Company Participants

Henry Hess - Chief Legal Counsel

Reenie McCarthy - Chief Executive Officer

Jim Carr - Chief Clinical Development Officer

Rob Weiskopf - Chief Financial Officer

Brian Blakey - Chief Business Officer

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Yi Chen - H.C. Wainwright


Greetings. Welcome to the Stealth BioTherapeutics Fiscal Year 2020 Financial Results and recent Business Highlights. At this all participants will be in listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.

At this time, I’ll turn the conference over to Henry Hess, Chief Legal Counsel.

Mr. Hess, you may begin.

Henry Hess

Good morning. I'd like to remind listeners that management will be making forward-looking statements on today's call, including, for example, the company's expected timeline and plans for development of Elamipretide and other pipeline programs, regulatory interactions and financial position and cash runway.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of Stealth Form 20-F filed with the SEC on April 1st, 2020.

While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so if our views change.

Now, I'd like to turn over the call to Reenie McCarthy, Stealth's, CEO. Reenie?

Reenie McCarthy

Thank you, Henry. And thanks to those on the line for joining us today. With me and Henry on the line are Jim Carr, our Chief Clinical Development Officer; Rob Weiskopf, our Chief Financial Officer; and Brian Blakey, our Chief Commercial Officer.

So during 2020, our team rallied from very challenging

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.